Aesica has named Ian Muir as the company’s first commercial managing director, effective February 24.
The contract development and manufacturing (CDMO) firm Aesica said the creation of the role reflects the company’s decision to focus on ‘core commercial activities’.
Muir’s responsibilities will cover manufacture of active pharmaceutical ingredients, formulation development and formulated products, while he will also lead the expansion of the business into new markets, such as China and Japan.
He joins from the CDMO Catalent where he was responsible for the global provision of contract development and manufacturing services for oral dose forms.
Muir’s previous experience also includes commercial responsibilities in the US, Australia and Japan.
Aesica’s CEO Robert Hardy said: “Ian brings strong commercial business knowledge and has proven experience of delivering growth and will play a pivotal role in driving further business growth for Aesica across API, formulation development and formulated products.”